Effects of etonogestrel implant on quality of life, sexual function, and pelvic pain in women suffering from endometriosis: results from a multicenter, prospective, observational study
Progestins are successfully employed as treatment for endometriosis. Our study evaluates the effects of the etonogestrel (ENG) implant on pelvic pain, quality of life, and sexual function in women requiring long-term reversible contraception and presenting ovarian cysts of probable endometriotic origin.
We enrolled 25 women asking for contraception with the ENG implant and presenting a cyst with the ultrasound features of an endometrioma and pain symptoms. Patients were interviewed on pain symptoms (dysmenorrhea, dyspareunia, dyschezia, and dysuria) using a VAS score (0–10), on quality of life (QoL) using the Short Form-36 questionnaire, and on sexual activity using the Female Sexual Function Index (FSFI) questionnaire before inserting the implant (T0) and after 6 (T1) and 12 months (T2).
We found a significant decrease in dysmenorrhea and dyspareunia VAS scores comparing baseline scores to 6 and 12 months. After 12 months, the bodily pain, general health, vitality, social functioning, and mental health domains of the QoL score were significantly improved. The total FSFI score results increased in comparison with baseline both at 6 and 12 months. In particular, we highlighted a significant improvement in desire, satisfaction, and pain domains already at 6 months; the arousal domain improved only after 12 months. Finally, mean diameters of endometrioma-like cysts were not changed after 12 months of treatment.
Etonogestrel implants seem to be able to reduce pelvic pain, improve sexual function, and quality of life in patients with ovarian cysts suspected of endometriotic origin.
KeywordsEndometriosis Etonogestrel implant Pelvic pain Quality of life Contraception
AS: manuscript writing. NR: data collection. PG: manuscript writing. MG: data collection. ASL: manuscript editing. CC: project supervision.
This study was not supported by any grant/fund.
Compliance with ethical standards
Conflict of interest
The authors have no proprietary, financial, professional, or other personal interest of any nature in any product, service, or company.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 18.Walch K, Unfried G, Huber J et al (2009) Implanon® versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis—a pilot study. Contraception 79:29–34. https://doi.org/10.1016/j.contraception.2008.07.017 CrossRefPubMedGoogle Scholar
- 19.Royal College of Obstetricians and Gynaecologist (2006) Endometriosis, investigation and management. RCOG Green- top Guideline No. 24Google Scholar
- 23.Di Carlo C, Guida M, De Rosa N et al (2015) Bleeding profile in users of an etonogestrel sub-dermal implant: effects of anthropometric variables. An observational uncontrolled preliminary study in Italian population. Gynecol Endocrinol 31:491–494. https://doi.org/10.3109/09513590.2015.1018163 CrossRefPubMedGoogle Scholar
- 28.Strowitzki T, Faustmann T, Gerlinger C, Seitz C (2010) Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 151:193–198. https://doi.org/10.1016/j.ejogrb.2010.04.002 CrossRefPubMedGoogle Scholar
- 29.Harada T, Momoeda M, Taketani Y et al (2009) Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis-a randomized, double-blind, multicenter, controlled trial. Fertil Steril 91:675–681. https://doi.org/10.1016/j.fertnstert.2007.12.080 CrossRefPubMedGoogle Scholar
- 31.Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S (2011) Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril 95:492–496. https://doi.org/10.1016/j.fertnstert.2010.08.042 CrossRefPubMedGoogle Scholar